Equities Analysts Offer Predictions for ORIC Q1 Earnings

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) – Analysts at HC Wainwright increased their Q1 2026 earnings estimates for shares of Oric Pharmaceuticals in a note issued to investors on Tuesday, February 24th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.31) per share for the quarter, up from their previous forecast of ($0.37). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Oric Pharmaceuticals’ current full-year earnings is ($2.17) per share. HC Wainwright also issued estimates for Oric Pharmaceuticals’ Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.34) EPS and FY2026 earnings at ($1.28) EPS.

A number of other research firms also recently weighed in on ORIC. JPMorgan Chase & Co. increased their price target on Oric Pharmaceuticals from $17.00 to $20.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Thursday, January 22nd. Evercore initiated coverage on Oric Pharmaceuticals in a research report on Thursday, November 20th. They issued an “outperform” rating and a $25.00 target price on the stock. Wall Street Zen lowered shares of Oric Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, November 23rd. Finally, Wells Fargo & Company upped their price objective on Oric Pharmaceuticals from $19.00 to $25.00 and gave the stock an “overweight” rating in a research note on Monday, December 8th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.20.

Oric Pharmaceuticals Trading Down 0.4%

Shares of NASDAQ ORIC opened at $13.45 on Thursday. The firm’s 50-day moving average is $10.39 and its 200-day moving average is $11.00. Oric Pharmaceuticals has a 1 year low of $3.90 and a 1 year high of $14.93. The firm has a market capitalization of $1.35 billion, a PE ratio of -8.85 and a beta of 1.35.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.04.

Insider Transactions at Oric Pharmaceuticals

In related news, insider Pratik S. Multani sold 10,720 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $9.06, for a total value of $97,123.20. Following the completion of the transaction, the insider owned 68,149 shares of the company’s stock, valued at $617,429.94. The trade was a 13.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Dominic Piscitelli sold 52,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $13.51, for a total transaction of $702,520.00. Following the completion of the transaction, the chief financial officer owned 68,148 shares of the company’s stock, valued at $920,679.48. The trade was a 43.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 106,814 shares of company stock valued at $1,199,135. 6.82% of the stock is currently owned by company insiders.

Institutional Trading of Oric Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ORIC. Nisa Investment Advisors LLC lifted its holdings in shares of Oric Pharmaceuticals by 17,300.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,436 shares of the company’s stock worth $25,000 after acquiring an additional 2,422 shares during the last quarter. Federation des caisses Desjardins du Quebec grew its holdings in Oric Pharmaceuticals by 100.0% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock worth $33,000 after acquiring an additional 2,000 shares during the period. Assetmark Inc. acquired a new position in Oric Pharmaceuticals in the third quarter valued at approximately $37,000. Caitong International Asset Management Co. Ltd boosted its stake in Oric Pharmaceuticals by 184.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock worth $37,000 after acquiring an additional 2,936 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Oric Pharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock valued at $39,000 after purchasing an additional 977 shares during the period. 95.05% of the stock is currently owned by institutional investors.

Key Stories Impacting Oric Pharmaceuticals

Here are the key news stories impacting Oric Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised quarterly and FY2026 EPS estimates, narrowed the FY loss forecast (to ($1.28) from ($1.52)), kept a “Buy” rating and raised its price target to $25 — a material analyst upgrade supporting upside. Read More.
• Positive Sentiment: Oric reported a Q4 earnings beat (EPS -$0.30 vs. -$0.34 consensus), which acted as a near-term catalyst and likely drove recent buying interest. Read More.
• Positive Sentiment: Multiple broker actions (Wedbush Outperform; Piper Sandler, JPMorgan and others with overweight/buy calls and higher targets) have created a bullish analyst consensus — Zacks highlights the mean price target implying ~58% upside, which can attract momentum buyers. Read More.
• Neutral Sentiment: Consensus still shows multi-quarter losses (current full‑year consensus ~($2.17) per share), so the stock’s upside depends on continued clinical progress, margin improvement and execution. Read More.
• Neutral Sentiment: Institutional ownership is very high (~95%); while this can stabilize the stock, it may also limit new institutional inflows unless conviction strengthens. Read More.
• Negative Sentiment: CFO Dominic Piscitelli sold 52,000 shares (~$702.5k at ~$13.51), cutting his stake by ~43% — insider selling can be perceived negatively and may temper the rally. SEC Form 4: Read More.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.